help button home button The Oncologist http://theoncologist.alphamedpress.org/subscriptions/etoc.dtl
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow eLetters: Submit a response to this article
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nahta, R.
Right arrow Articles by Esteva, F. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nahta, R.
Right arrow Articles by Esteva, F. J.
The Oncologist, Vol. 8, No. 1, 5–17, February 2003
© 2003 AlphaMed Press


ORIGINAL PAPER
BREAST CANCER

Growth Factor Receptors in Breast Cancer: Potential for Therapeutic Intervention

Rita Nahtaa, Gabriel N. Hortobágyia, Francisco J. Estevaa,b

a Departments of Breast Medical Oncology and b Molecular and Cellular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA

Correspondence: Francisco J. Esteva, M.D., Ph.D., Departments of Breast Medical Oncology and Cellular and Molecular Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 424, Houston, Texas 77030, USA. Telephone: 713-792-2817; Fax: 713-745-5768; e-mail: festeva{at}mdanderson.org

Increased expression and activation of receptor tyrosine kinases occurs frequently in human breast carcinomas. Several therapies targeting these receptors are currently in clinical trials. Therapeutic strategies include blockade of individual receptors with monoclonal antibodies and inhibition of tyrosine kinase function. Trastuzumab is the first of these biologic therapies to be approved for patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic breast cancer. Novel trastuzumab-based combinations are being investigated in patients with advanced breast cancer. Large clinical trials have also been launched in the adjuvant setting. Small molecules that inhibit specific tyrosine kinases (e.g., epidermal growth factor receptor, HER2) are in phase I and phase II clinical trials. Other growth-factor-targeted drugs that have reached clinical development include STI571 and antibodies directed at the insulin-like growth factor pathway. Biologic therapies directed against these important receptors are promising. In this review we discuss challenges and opportunities for the development of growth-factor-targeted approaches for the treatment of breast cancer.

Key Words. Breast neoplasm • Biologic therapy • Prognostic markers • IGF-IR • EGFR • HER2 • Monoclonal antibodies • Tyrosine kinase inhibitors




This article has been cited by other articles:


Home page
JNMHome page
D. L. Costantini, K. Bateman, K. McLarty, K. A. Vallis, and R. M. Reilly
Trastuzumab-Resistant Breast Cancer Cells Remain Sensitive to the Auger Electron-Emitting Radiotherapeutic Agent 111In-NLS-Trastuzumab and Are Radiosensitized by Methotrexate
J. Nucl. Med., September 1, 2008; 49(9): 1498 - 1505.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
R. A. Jones, C. I. Campbell, J. J. Petrik, and R. A. Moorehead
Characterization of a Novel Primary Mammary Tumor Cell Line Reveals that Cyclin D1 Is Regulated by the Type I Insulin-Like Growth Factor Receptor
Mol. Cancer Res., May 1, 2008; 6(5): 819 - 828.
[Abstract] [Full Text] [PDF]


Home page
Journal of Pharmacy PracticeHome page
M. B. Toma and P. J. Medina
Update on Targeted Therapy--Focus on Monoclonal Antibodies
Journal of Pharmacy Practice, February 1, 2008; 21(1): 4 - 16.
[Abstract] [PDF]


Home page
The OncologistHome page
B. Moy and P. E. Goss
Lapatinib-Associated Toxicity and Practical Management Recommendations
Oncologist, July 1, 2007; 12(7): 756 - 765.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
A. Araujo, R. Ribeiro, I. Azevedo, A. Coelho, M. Soares, B. Sousa, D. Pinto, C. Lopes, R. Medeiros, and G. V. Scagliotti
Genetic Polymorphisms of the Epidermal Growth Factor and Related Receptor in Non-Small Cell Lung Cancer--A Review of the Literature
Oncologist, February 1, 2007; 12(2): 201 - 210.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Kubetzko, E. Balic, R. Waibel, U. Zangemeister-Wittke, and A. Pluckthun
PEGylation and Multimerization of the Anti-p185HER-2 Single Chain Fv Fragment 4D5: EFFECTS ON TUMOR TARGETING
J. Biol. Chem., November 17, 2006; 281(46): 35186 - 35201.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
B. Moy and P. E. Goss
Lapatinib: Current Status and Future Directions in Breast Cancer
Oncologist, November 1, 2006; 11(10): 1047 - 1057.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
A. Khambalia, M. E. Latulippe, C. Campos, C. Merlos, S. Villalpando, M. F. Picciano, and D. L. O'Connor
Milk Folate Secretion Is Not Impaired during Iron Deficiency in Humans
J. Nutr., October 1, 2006; 136(10): 2617 - 2624.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
K. L. Gable, B. A. Maddux, C. Penaranda, M. Zavodovskaya, M. J. Campbell, M. Lobo, L. Robinson, S. Schow, J. A. Kerner, I. D. Goldfine, et al.
Diarylureas are small-molecule inhibitors of insulin-like growth factor I receptor signaling and breast cancer cell growth.
Mol. Cancer Ther., April 1, 2006; 5(4): 1079 - 1086.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
B. Jiang, W. Liu, H. Qu, L. Meng, S. Song, T. Ouyang, and C. Shou
A Novel Peptide Isolated from a Phage Display Peptide Library with Trastuzumab Can Mimic Antigen Epitope of HER-2
J. Biol. Chem., February 11, 2005; 280(6): 4656 - 4662.
[Abstract] [Full Text] [PDF]




HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS
http://theoncologist.alphamedpress.org/misc/eLetters.shtml

Copyright © 2003 by AlphaMed Press.